Collaboration to develop modular facility proof-of-concept for multi-modal bioprocessing activities

Vaccine Insights 2023; 1(6), 325

DOI: 10.18609/vac/2022.045

Published: 18 January 2023
Jerome Dalin, Thomas Hauser

Watch the video or read the poster to learn about:

  • Why modular, multimodal bioprocessing is an important future trend
  • The specific design and timelines for the proof-of-concept facility design
  • How this modular facility approach can be leveraged for your specific requirements
  • A roadmap for the future, including improved sustainability and greater automation

Jerome Dalin, Senior Consultant– EMEA Traditional Modalities, Bioprocessing Strategy Operationalization, Merck. Jerome started his career at Sanofi Pasteur 20 years ago in vaccine process development in France before joining Merck in 2013 to manage bioprocessing sales with vaccine project coordination at a global level. In his current role, Jerome is leading strategic initiatives and supporting go-to-market strategies with a special focus on traditional modalities.

Thomas Hauser, Business Development Manager, EMEA, G-CON. Thomas is working for G-CON Manufacturing in the EMEA region in a drive to bring forward the pharmaceutical facility of the future concept. He is also supporting companies in the life science segment in expansion strategies, strategic facility implementation, start-up support, and pharmaceutical packaging supply and technologies. Before 2020, Thomas worked in business development, strategic implementation, and sales in the pharmaceutical packaging field. He has more than 25 years of experience working with the global life science industry.